The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising
Garver DL, Bissette G, Yao JK, Nemeroff CB (1991) Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients
there are so many options for you to choose from
For individuals exploring peptide therapy for arthritis, joint pain, inflammation support, or recovery optimization, Eternity Health Partners provides guidance tailored to each patients unique needs and wellness goals
But thats not allSemaglutide injections also excels in reducing the risk of heart disease and diabetes